Overview

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696
Olmesartan
Olmesartan Medoxomil
Sacubitril and valsartan sodium hydrate drug combination